Öffentliches Studienregister des CCC-München

Studie ADAPT Cycle

Studie Studiendesign Status Ein-/Auschlusskriterien Therapie Teilnehmer Dokumente Berechtigungen Tumorboards

Studie
World
Studienakronym
:
ADAPT Cycle
World
Vollständiger Titel
:

Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer

World
Beschreibung
:

The WSG ADAPT trial program is one of the first new generation trials addressing the issue of individualization of (neo)-adjuvant decision-making in early breast cancer (EBC) in a subtype-specific manner. The first WSG ADAPT umbrella trial (NCT01779206) aimed to establish early predictive molecular surrogate markers for response after a short 3-week induction treatment.
The goals of the WSG ADAPT trial program - early response assessment and subtype-specific therapy tailoring to those patients who are most likely to benefit - have contributed to the very positive national and international feedback to the ADAPT concept as a whole.
The aim of this ADAPTcycle phase-III-trial is to investigate whether the intermediate-risk patient group identified during the screening phase derives additional benefit from treatment with ribociclib in combination with ET compared to chemotherapy (followed by adjuvant ET).

World
EudraCT-Nr.
:
World
Zuständige Einrichtung
:
Frauenklinik IN, Telefon: 089440054111
Krankheitsentitäten
Klassifikation Code Beschreibung
- Brustkrebs
Studiendesign
World
Studientyp
:
Interventionsstudie
World
Verblindungstyp
:
Offen
World
Studienphase
:
III
Status
World
Status
:
Rekrutierung aktiv
Voten
World
Ethikkommission - Votum
:
Unbekannt
Initiierung & Abschluß
World
Abschlussdatum (Plan / Ist)
:
2024-04-01 / Unbekannt
Therapie
World
Therapielinie
:
1
Teilnehmer
Funktion Vorname Nachname Einrichtung
World Hauptprüfer NADIA HARBECK Keine Organisationseinheit angegeben Magnifier